COR2ED Medical Education

▶️ Neurological symptoms of hypophosphatasia: unifyrare.com/en/closing-t...

Programme initiated and funded by Alexion, AstraZeneca Rare Disease. Brought to you by COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0101 | Dec 2025

We're proud to share that more than 50k HCPs now follow us online!🎉

>25k YouTube subscribers
>25k social media followers

Follow us for engaging #medicaleducation developed by renowned medical experts & endorsed by Medical Societies & Patient Advocacy Groups
www.youtube.com/@cor2edthehe...

#MedSky

ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice

On-demand video and slides from an Experts Knowledge Share event

▶️ cor2ed.com/gi-connect/p...

Supported by an Independent Educational Grant from Amgen

#MedEd #MedicalEducation

#Hypophosphatasia across 3 generations – can you help make their dream a reality?

▶️ unifyrare.com/en/closing-t...

Programme initiated and funded by Alexion, AstraZeneca Rare Disease. Brought to you by COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0099 | Dec 2025

Closing the Gap in HPP Care 2025

webapp.spotme.com/login/alexio...

📅 2 & 4 December | Live sessions

Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025

Today is #WorldHPPDay

#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently

In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺

This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095

Rethinking HPP (hypophosphatasia)

➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently

Watch the video (GL/UNB-H/0087) for key facts 📺

This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases

Colleagues at #ESMO25 , Join our Collaborators at COR2ED and Dr. Lizzy Smyth straight from Berlin 👉 cor2ed.com/esmo-2025/up...

Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.

Colleagues at #ESMO25
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides

cor2ed.com/esmo-2025/on...

Prof. Viktor Grünwald shares his renal cell carcinoma highlights from ESMO 2025 as he reviews the latest data from the LenCabo, KEYMAKER-U03 and CLEAR studies. He also discusses staging of disease with the radiolabelled peptide ([68Ga]Ga-DPI-4452).

cor2ed.com/esmo-2025/re...

Dear Colleagues, Our Collaborators at COR2ED Invite you to watch Highlights from #ESMO25
WATCH HERE 👉 cor2ed.com/esmo-2025/br...

Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND

Exploring the role of targeted radiopharmaceutical treatment in NETs

Experts discuss PRRT and emerging strategies in neuroendocrine tumours

📹 Watch the video

Supported by an Independent Educational Grant from ITM

#MedEd #MedSky

How can new clinical trials in radioligand therapy impact clinical practice in #NET treatment strategies?

Find out in this new #MedEd video from medical experts

cor2ed.com/net-connect/...

Supported by an Independent Educational Grant from ITM

@nanets.bsky.social #MedSky #medicaleducation 📷

Improving acne vulgaris with multimodal treatment strategies | COR2ED In this micro learning module, developed by experts Prof. Alison Layton and Prof. Dr Falk Ochsendorf, you will explore multimodal treatment strategies for

📢 New #dermatology micro learning!

Improving acne vulgaris with multimodal treatment strategies

>> cor2ed.com/dermatology-...

📺 4-min video, downloadable flashcard & slides, and accredited assessment

Supported by an Independent Educational Grant from Glenmark Pharmaceuticals

#MedSky

ADC breast cancer trials to look out for in 2025 ⬇️

#MedSky #MedEd

🔎 Expert insights on recent #BreastCancer data

Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25

Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...

Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social

Early relapsed/refractory multiple myeloma (RRMM): best practices in management | COR2ED

🚨 Best practices in managing early relapsed/refractory multiple myeloma

3-part video series with expert insights & downloadable slide sets
⬇️
cor2ed.com/lymphoma-mye...

Supported by an Independent Educational Grant from Menarini Stemline Oncology

#MedSky #MedEd #RRMM

Navigating advanced HCC: treatment strategies beyond immunotherapy (IO) | COR2ED In this micro learning, developed by experts Assoc. Prof. Lorenza Rimassa and Dr Amit Singal, you will learn about treatment strategies for patients who

➡️Tx strategies for pts w/ advanced #HCC who are ineligible for #immunotherapy or with progression on #IO

👉 cor2ed.com/hcc-connect/...

Endorsed by @digestivecancerseu.bsky.social @bluefaeryliver.bsky.social @aasldnews.bsky.social @europeliver.bsky.social

Supported by an IME Grant from Bayer #meded

Congratulations to the newly elected ESMO Directors & Nomination Committee members!

A special mention to:
👏 GI CONNECT's Dr @lizzysmyth.bsky.social
👏 PRECISION ONCOLOGY CONNECT's Prof. Ulrik Lassen
👏 Prof. Rachel Riechelmann, who has collaborated with NET CONNECT

#MedicalEducation #ESMO #MedSky

Rethinking hypophosphatasia (HPP) diagnosis and disease burden | COR2ED

📹 Watch the video > cor2ed.com/n-connect/pr...

Video: The evolution of our understanding that led us to rethink #hypophosphatasia (HPP) 💡

w/ Dr Chad Deal

Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074

#MedEd #MedSky #EULAR2025

Highlights from ASCO 2025 | COR2ED

📣Update from #ASCO25

Expert insights on the latest data: cor2ed.com/n-connect/pr...

#NSCLC #ProstateCancer #GICancer #BreastCancer #OvarianCancer #CervicalCancer

NSCLC update supported by an Independent Educational Grant from Bayer.Other updates supported by COR2ED

#MedEd @lizzysmyth.bsky.social

Rethinking hypophosphatasia (HPP) diagnosis and disease burden | COR2ED

📹 Watch the video: cor2ed.com/n-connect/pr...

Video: Recognising #hypophosphatasia (HPP)🔍

- Key manifestations
- Common misdiagnoses

w/ Dr Chad Deal

Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074

#MedEd #EULAR2025

ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium | COR2ED In this conference update video, Profs. Wolfgang Janni, Sherko Kümmel and Michail Ignatiadis provide key insights from the highly anticipated ESMO Breast

📣Highlights from #ESMO Breast Cancer 2025 Satellite Symposium

Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer

cor2ed.com/n-connect/pr...

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only

Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) | COR2ED Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive, with a poor prognosis. It is often diagnosed late, and by this time,

Chemotherapy strategies in mPDAC

➡️How to choose & optimise the different chemotherapeutic options at 1st & 2nd line

w/ Profs. Efrat Dotan & Shubham Pant

📹 Watch the video/listen on Spotify/Apple cor2ed.com/gi-connect/p...

Supported by an Independent Educational Grant from Ipsen USA

#MedEd

Chemotherapy strategies for metastatic pancreatic ductal adenocarcinoma | COR2ED In this 2-part video animated series, medical oncologists Prof Eileen O’Reilly and Prof Efrat Dotan provide an overview of the different treatment options

New 2-part animated video series! 🎬

Ep.1 ➡️ 1st line chemotherapy options, key trial data & considering targeted therapy

Ep.2 ➡️ 2nd line chemotherapy options & how earlier treatments impact sequencing

cor2ed.com/gi-connect/p...

Supported by an Independent Educational Grant from Ipsen USA

#MedEd

The HER2 diagnostic and treatment landscape in NSCLC: Episode 2 | COR2ED This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in non-small cell lung cancer (NSCLC), hosted by the

🎙️#MedEd podcast

'The #HER2 diagnostic and treatment landscape in #NSCLC'

> Ep. 2: Navigating common treatment scenarios in HER2-mutant NSCLC

➡️w/ @oncbrothers.bsky.social

Watch the video/listen on Spotify/Apple:
cor2ed.com/lung-connect...

Supported by an Independent Educational Grant from Bayer

The HER2 diagnostic and treatment landscape in NSCLC: Episode 1 | COR2ED This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in non-small cell lung cancer (NSCLC), hosted by the

📢 New #lungcancer podcast!

'The #HER2 diagnostic and treatment landscape in #NSCLC'

>> Episode 1: Identifying HER2-directed NSCLC

w/@oncbrothers.bsky.social

Watch the video/listen on Spotify/Apple👇
cor2ed.com/lung-connect...

Supported by an Independent Educational Grant from Bayer

#MedEd

Survey on the evolving role of the oncology nurse in the USA | COR2ED Access the paper online here: The Evolving Role of the Oncology Nurse in the United States of America.   The survey results highlight:  How roles and

What do oncology nurses in the USA think about the ways their roles are changing?

GI NURSES CONNECT set out to answer this question in a recent survey 📊

The findings were published in the journal 'Healthcare'

Find out more: cor2ed.com/gi-nurses-co...

Supported by an IME grant from Bayer

#MedEd

The expanding role of immunotherapy in HCC | COR2ED In this micro learning developed by experts Prof. Aiwu Ruth He and Prof. Beau Toskich, you’ll learn about the expanding role of immunotherapy (IO) in

HCC micro learning 🎓

The expanding role of immunotherapy in HCC

> Combining locoregional & systemic treatments in intermediate HCC

Video, slides, flashcard + accredited assessment
👉 cor2ed.com/hcc-connect/...

AstraZeneca has provided a sponsorship grant towards this independent programme
#MedEd

ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial | COR2ED Prof. François-Clément Bidard and Dr Barbara Pistilli share expert insights on the latest TROPION-Breast01 update, presenting the final OS results from

TROPION-Breast01 final OS results did not reach statistical significance; however, subsequent ADC Tx may have influenced survival outcomes

Update on the latest data from #ESMO Virtual Plenary 2025👇
cor2ed.com/breast-cance...

Supported by an Independent Educational Grant from AstraZeneca

#MedEd